Evaluation of the effect of sorafenib using serum NX-des-γ-carboxyprothrombin in patients with hepatocellular carcinoma

Hepatology Research

Volumn 43, Issue 10, 2013, Pages 1064-1070

  Miyahara, Koji ^a   Nouso, Kazuhiro ^a   Morimoto, Yuki ^a   Tomoda, Takeshi ^a   Kobayashi, Sayo ^a   Takeuchi, Yasuto ^a   Hagihara, Hiroaki ^a   Kuwaki, Kenji ^a   Ohnishi, Hideki ^a   Ikeda, Fusao ^a   Miyake, Yasuhiro ^a   Nakamura, Shinichiro ^a   Shiraha, Hidenori ^a   Takaki, Akinobu ^a   Yamamoto, Kazuhide ^a   Takuma, Yoshitaka ^b   Takabatake, Hiroyuki ^b   Morimoto, Youichi ^b   Fujioka, Shin Ichi ^c   Osawa, Toshiya ^c   Kariyama, Kazuya ^d   Toshimori, Junichi ^e   Kobashi, Haruhiko ^e   Miyatake, Hirokazu ^f   Iwadou, Shouta ^f   Kobayashi, Yoshiyuki ^f   Uematsu, Shuji ^f   Okamoto, Ryoichi ^f   Araki, Yasuyuki ^f   Tatsukawa, Masafumi ^g   Yabushita, Kazuhisa ^g   Shimoe, Toshinari ^g   Sakaguchi, Kohsaku ^g   Sakata, Tatsuro ^h   Kaneyoshi, Toshihiko ^h   Miyashita, Manabi ⁱ   Makino, Yasuhiro ⁱ   Moriya, Akio ^j   Ando, Masaharu ^j   Baba, Nobuyuki ^k   Seno, Tomonori ^k   Nagano, Takuya ^k   Takaguchi, Koichi ^k   Matsumoto, Eiji ^l   Takayama, Hiroki ^m   more..

^a OKAYAMA UNIVERSITY   (Japan)

^b KURASHIKI CENTRAL HOSPITAL   (Japan)

^c OKAYAMA SAISEIKAI GENERAL HOSPITAL   (Japan)

^d Okayama Citizens Hospital   (Japan)

^e Okayama Red Cross Hospital   (Japan)

^f HIROSHIMA CITY HOSPITAL   (Japan)

^g Fukuyama City Hospital   (Japan)

^h NATIONAL HOSPITAL ORGANIZATION FUKUYAMA MEDICAL CENTER   (Japan)

ⁱ IWAKUNI NATIONAL HOSPITAL   (Japan)

^j Mitoyo General Hospital   (Japan)

^k KAGAWA PREFECTURAL CENTRAL HOSPITAL   (Japan)

^l Sumitomo Besshi Hospital   (Japan)

^m Tsuyama Central Hospital   (Japan)

more..

Author keywords

Des carboxyprothrombin; Hepatocellular carcinoma; NX des carboxyprothrombin; Sorafenib

Indexed keywords

BIOLOGICAL MARKER; DECARBOXYPROTHROMBIN; NX DES GAMMA CARBOXYPROTHROMBIN; SORAFENIB; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; HUMAN; LIVER CELL CARCINOMA; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; TREATMENT RESPONSE;

EID: 84885025687     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12055     Document Type: Article

References (20)

1. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-1917.
2. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236.
3. Llovet JM. Updated treatment approach to hepatocellular carcinoma. J Gastroenterol 2005; 40: 225-235.
4. Llovet JM, Ricci S, Mazzaferro V etal. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
5. Cheng AL, Kang YK, Chen Z etal. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
6. Nakamura S, Nouso K, Sakaguchi K etal. Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size. Am J Gastroenterol 2006; 101: 2038-2043.
7. Tang W, Miki K, Kokudo N etal. Des-gamma-carboxy prothrombin in cancer and non-cancer liver tissue ofpatients with hepatocellular carcinoma. Int J Oncol 2003; 22: 969-975.
8. Inagaki Y, Tang W, Makuuchi M, Hasegawa K, Sugawara Y, Kokudo N. Clinical and molecular insights into the hepatocellular carcinoma tumour marker des-γ-carboxyprothrombin. Liver Int 2011; 31: 22-35.
9. Park WH, Shim JH, Han SB etal. Clinical utility of des-γ-carboxyprothrombin kinetics as a complement to radiologic response in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. J Vasc Interv Radiol 2012; 23: 927-936.
10. Kuzuya T, Asahina Y, Tsuchiya K etal. Early decrease in α-fetoprotein, but not des-γ-carboxy prothrombin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma. Oncology 2011; 81: 251-258.
11. Nakazawa T, Hidaka H, Shibuya A, Koizumi W. Rapid regression of advanced hepatocellular carcinoma associated with elevation of des-gamma-carboxy prothrombin after short-term treatment with sorafenib - a report of two cases. Case Rep Oncol 2010; 3: 298-303.
12. Ueshima K, Kudo M, Takita M etal. Des-γ-carboxyprothrombin may be a promising biomarker to determine the therapeutic efficacy of sorafenib for hepatocellular carcinoma. Dig Dis 2011; 29: 321-325.
13. Murata K, Suzuki H, Okano H, Oyamada T, Yasuda Y, Sakamoto A. Hypoxia-induced des-gamma-carboxy prothrombin production in hepatocellular carcinoma. Int J Oncol 2010; 36: 161-170.
14. Toyoda H, Kumada T, Osaki Y, Tada T, Kaneoka Y, Maeda A. Novel method to measure serum levels of des-gamma-carboxy prothrombin for hepatocellular carcinoma in patients taking warfarin: a preliminary report. Cancer Sci 2012; 103: 921-925.
15. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: 52-60.
16. Ueda N, Shiraha H, Fujikawa T etal. Exon 2 deletion splice variant of gamma-glutamyl carboxylase causes des-gamma-carboxy prothrombin production in hepatocellular carcinoma cell lines. Mol Oncol 2008; 2: 241-249.
17. Malaguarnera G, Giordano M, Paladina I, Berretta M, Cappellani A, Malaguarnera M. Serum markers of hepatocellular carcinoma. Dig Dis Sci 2010; 55: 2744-2755.
18. Johnson PJ. Role of alpha-fetoprotein in the diagnosis and management of hepatocellular carcinoma. J Gastroenterol Hepatol 1999; 14: S32-36.
19. Shao YY, Lin ZZ, Hsu C, Shen YC, Hsu CH, Cheng AL. Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma. Cancer 2010; 116: 4590-4596.
20. Yau T, Yao TJ, Chan P etal. The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib. Oncologist 2011; 16: 1270-1279.